Piedmont Heart Grand Rounds:
Cardiometabolic syndrome is a combination of metabolic dysfunctions that increase the risk for cardiovascular disease and type 2 diabetes. Piedmont Heart cardiologist Dr. Jaime Burkle discusses cardiometabolic therapies, focusing on what he calls “arguably the most important new class of cardiovascular medications, SGL-2 inhibitors.” He helps cardiologists understand the benefits and risks of these new classes of drugs in cardiovascular morbidity and mortality.
CME Statement
The following planners and presenters have no relevant financial disclosures: Traci Gordon and Joseph Miller, M.D. Jaime Burkle, M.D., presenter for this session, reports that he has the following financial disclosures: Boehringer-Ingelheim -Speaker, Amgen -Speaker. All relevant financial relationships have been mitigated by Piedmont Healthcare.
Piedmont Healthcare is accredited by the Medical Association of Georgia to provide continuing medical education for physicians. Piedmont Healthcare designates this enduring activity for a maximum of .50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive CME credit, please click the button below to complete competency questions and evaluation.
Earn CME Credit
References
- Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128.
- Docherty KF, Jhund PS, Anand I, et al. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation2020;142:1623-32.
- Heerspink HJ, Sjöström CD, Jongs N, et al. Effects of Dapagliflozin on Mortality in Patients With Chronic Kidney Disease: A Pre-specified Analysis From the DAPA-CKD Randomized Controlled Trial.